1. Generics Bulletin
  2. >>Business
  3. >>Deals

Future Of Bankrupt Orchid In Doubt

Indian Appeal Body Rejects Dhanuka Rescue Of Orchid

 
• By Penelope MacRae

An Indian appellate tribunal has scuttled the acquisition of bankrupt Orchid Pharma by Dhanuka Labs, ruling that the deal contravened the country’s bankruptcy code.

Flowers
Cutting off Dhanuka’s rescue bid poses an existential threat to Orchid • Source: Shutterstock

The future of India’s bankrupt Orchid Pharma has been thrown up in the air once again. An appellate body has rejected Dhanuka Laboratories’ offer to acquire Orchid and put the debt-laden company back on the road to recovery. It is the second time a rescue bid for Orchid has collapsed and the news has sent the firm’s share price tumbling.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

As US Launches Pharma Probe, AAM Warns Tariffs ‘Will Only Amplify Problems’

 
• By Dave Wallace

News of a fresh US investigation into the pharma sector has sparked renewed concerns over the impact that US trade tariffs would have on the generics and biosimilars industry. The AAM has responded with a warning over the potential effects on shortages and access, while Medicines for Europe has proposed five key action areas to bolster the sector in Europe.

Sandoz Attacks Amgen Over US Enbrel Exclusivity

 
• By Dave Wallace

Having failed in US patent litigation over Amgen’s Enbrel, Sandoz is taking an alternative approach in trying to get its Erelzi biosimilar to market in the US ahead of patent expiry in 2029: launching an antitrust attack against the originator for “unlawfully extending and entrenching its monopoly."

Cipla Welcomes Abraxane ANDA Approval After Tackling Goa Compliance Issues

 
• By Dean Rudge

Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.